Prescription medicine
Selinexor Brand names: Xpovio
Selinexor (Xpovio) is a prescription medicine with an FDA approval on record since 2019. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the selinexor FDA label on DailyMed (effective May 12, 2026, Karyopharm Therapeutics Inc.); the NDA 212306 record on Drugs@FDA; every selinexor label on DailyMed.
Highlights of the record
FDA label of May 12, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageXPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ).
Forms and strengths
- 10 mg
- 20 mg
- 40 mg
- 50 mg
- 60 mg
- 80 mg
Film-coated tablet.
On the market
- Earliest approval on file
- July 3, 2019 Xpovio, Karyopharm Theraps; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- August 14, 2035 Xpovio tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 8,606 through July 30, 2026
What is selinexor used for?
From the label: indications and usageXPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). […]
Conditions named in the indications of selinexor's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Nuclear Export Inhibitor.
Source: FDA drug label (XPOVIO), Karyopharm Therapeutics Inc., effective May 12, 2026 (SPL set f6dd2682-75a6-4863-90a8-a3197f6f78a8), via openFDA; the full label on DailyMed
What does the patient leaflet for selinexor say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about XPOVIO?XPOVIO can cause serious side effects, including: Low platelet counts and low white blood cell counts are common with XPOVIO and can sometimes be severe or life-threatening. Low platelet counts. Low platelet counts can lead to bleeding which can sometimes cause death. Your healthcare provider may prescribe platelet transfusions or other treatments for your low platelet counts. Tell your healthcare provider right away if you have any bleeding or easy bruising during treatment with XPOVIO. Low white blood cell counts. You may have an increased risk of infection during treatment with XPOVIO. Tell your healthcare provider if you have any signs or symptoms of infection, including fever, chills, cough, shortness of breath, pain during urination, or feeling generally unwell. Your healthcare provider may prescribe antibiotics, or certain medicines to help increase your white blood cell count, if needed. Your healthcare provider will do blood tests before you start taking XPOVIO and often during the first 3 months of treatment and then as needed during treatment to monitor your blood cell counts. See “What are the possible side effects of XPOVIO?” for more information about side effects.
From the patient leaflet: What should I avoid while taking XPOVIO?XPOVIO can cause neurologic side effects. See “What are the possible side effects of XPOVIO?” below. If you have any neurologic side effects with XPOVIO, do not drive or operate heavy or dangerous machinery until your neurologic side effects go away. Avoid falling. Use care as needed to avoid falling due to neurologic side effects.
From the patient leaflet: How should I store XPOVIO?Store XPOVIO at or below 86°F (30°C). XPOVIO comes in a child-resistant blister pack. Keep XPOVIO and all medicines out of the reach of children.
Source: FDA drug label (XPOVIO), Karyopharm Therapeutics Inc., effective May 12, 2026 (SPL set f6dd2682-75a6-4863-90a8-a3197f6f78a8), via openFDA; the full label on DailyMed
Is there a generic for selinexor (Xpovio)?
No generic selinexor is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 11 patents for Xpovio tablets: the compound patent runs to August 14, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2019 earliest approval on file
- 2035 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the selinexor label say about other medicines?
The selinexor label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Loperamide | warnings and precautions | Provide standard anti-diarrheal agents, administer intravenous fluids to prevent dehydration and replace electrolytes as clinically indicated. |
Source: FDA drug label (XPOVIO), Karyopharm Therapeutics Inc., effective May 12, 2026 (SPL set f6dd2682-75a6-4863-90a8-a3197f6f78a8), via openFDA; the full label on DailyMed
What do FAERS reports show for selinexor?
The FDA Adverse Event Reporting System holds 8,606 reports that list selinexor among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 1,459 are coded as a death and 2,642 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as selinexor?
37 other medicines are given the same way (oral) and in the same FDA class as selinexor or labeled mainly for the same use (leukemia, lymphoma and myeloma), the same class first. Leukemia, lymphoma and myeloma lists all 98 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Lenalidomide | Leukemia, lymphoma and myeloma | 18 labelers | n/a | No current entry |
| Dasatinib | Leukemia, lymphoma and myeloma | 14 labelers | $26.46 per tablet 100 mg tablet | No current entry |
| Pomalidomide | Leukemia, lymphoma and myeloma | 11 labelers | n/a | No current entry |
| Imatinib | Leukemia, lymphoma and myeloma | 20 labelers | $0.624 per tablet 100 mg tablet | No current entry |
| Arsenic trioxide | Leukemia, lymphoma and myeloma | none listed | n/a | A presentation being discontinued |
| Nilotinib | Leukemia, lymphoma and myeloma | 6 labelers | n/a | No current entry |
| Hydroxyurea | Leukemia, lymphoma and myeloma | 10 labelers | $0.184 per capsule 500 mg capsule | No current entry |
| Cyclophosphamide | Leukemia, lymphoma and myeloma | 4 labelers | $1.67 per capsule 50 mg capsule | No current entry |
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Selinexor side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other